Yimeng Wang, Weiwei Li, Qian Zhang, Xiaoguang Gu, Xinglan He, Yuehua Men, Chunlei Zhang
DOI: 10.2340/00015555-3263

Cutaneous T-cell lymphoma (CTCL) represents a rare group of extranodal T-cell lymphoproliferative diseases. Due to poor clinical outcome of CTCL, there is an urgent need for new and improved therapies. A small molecule, IPA-3, which inhibits p21-activated kinase 1 (PAK1), has shown therapeutic potential in various types of malignancies. In the present study, the anti-tumor effect of IPA-3 and its underlying molecular mechanism was evaluated. High expression of phosphorylated-PAK1 (pho-PAK1) was seen in CTCL lesional skin compared to benign inflammatory dermatoses. IPA-3 could significantly inhibit the proliferation of 3 CTCL lines in a dose- and time-dependent manner. The percentage of apoptotic cells was higher in the treatment group. Further, IPA-3 treatment caused increased EGR1 protein levels and decreased apoptosis-related BCL-2 and pho-BAD protein levels. In summary, inhibition of pho-PAK1 has significant anti-tumor effects in CTCL cells and it can be explored as a future therapeutic option.

IPA-3, a small molecular inhibitor of p21-activated kinase 1 (PAK1) phosphorylation, has anti-tumor activity in multiple cancers. However, its role in cutaneous T-cell lymphoma and the underlying molecular pathogenesis are still unclear. This study investigates the role of IPA-3 on cutaneous T-cell lymphoma cells. Pho-PAK1 overexpression is seen in patients with cutaneous T-cell lymphoma. IPA-3 treatment induces apoptosis and inhibits cell growth by inducing EGR1 expression and simultaneously down-regulating the levels of BCL-2 and pho-BAD. Therefore, pho-PAK1 may be a potential tumor marker and therapeutic target of cutaneous T-cell lymphoma.